The limited expression of CD30 in normal tissues and its consistent overexpression in cHL and anaplastic large cell lymphoma (ALCL) have encouraged the development of CD30-directed therapy [4]. The gene discussed is TNFRSF8; the disease is anaplastic large cell lymphoma.